TScan Therapeutics, Inc. - Common Stock — Liquidità Trimestrale (NASDAQ:TCRX) | MetaTrader

Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 371.12 M332.71 M298.56 M262.23 M228.79 M201.99 M Totale passività 130.15 M122.51 M121.85 M118.2 M105.67 M105.07 M Patrimonio netto totale 240.97 M210.2 M176.71 M144.02 M123.12 M96.92 M Totale passività e patrimonio netto 371.12 M332.71 M298.56 M262.23 M228.79 M201.99 M Debito totale 32.07 M32.18 M32.3 M32.41 M32.53 M32.65 M Indebitamento netto 32.07 M32.18 M-185.75 M-152.04 M-119.87 M-95.4 M

Notizie

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

H.C. Wainwright conferma Buy su Tscan con target di 7$

TScan Therapeutics annuncia le dimissioni del vicepresidente finanziario

Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street - TipRanks.com

Gli EPS di Tscan Therapeutics hanno battuto le aspettative per 0,09$, il fatturato supera le previsioni

Tscan Therapeutics earnings beat by $0.09, revenue topped estimates

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan completa l’arruolamento nella coorte dello studio, riceve l’autorizzazione FDA

TScan completes enrollment in trial cohort, receives FDA clearance

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates

Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?